Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Catalyst Pharmaceutical Partners, Inc.
Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Catalyst Pharmaceutical Partners, Inc. Business Wire SAN DIEGO -- October 18, 2013 Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) violated state or federal laws. Catalyst Pharmaceutical shares were down over 25% on October 18, 2013 in early morning trading. An article released prior to markets’ opening on October 18, 2013 by The Street discussed Catalyst’s drug Firdapse, which is currently in trials. This article raised concerns that Catalyst investors may have bought the Company’s shares with the belief that Firdapse is an up and coming orphan drug. Catalyst shareholders may not be aware that there is a competing drug made by Jacobus (3,4-Dap) that treats the same disease. Both drugs, Firdapse and 3,4-Dap, treat Lambert-Eaton Myasthenic Syndrome (LEMS) -- a rare, neuromuscular disease which causes progressive muscle weakness. Jacobus (3,4-Dap), an equivalent drug to Firdapse, has been provided to patients in the treatment of LEMS for over 20 years for free. Though 3,4-Dap has not been formally approved by the FDA, each free prescription of the drug for the last 20 years has been approved by the FDA under a "compassionate use" directive. Jacobus is now working to stop Catalyst from gaining FDA approval for Firdapse in order to keep access free for LEMS patients. To do so, Jacobus is now conducting a directly competitive clinical trial with the intent of getting the drug formally approved by the FDA. Johnson & Weaver’s investigation will seek to determine if investors were previously misled by Catalyst Pharmaceutical officers or directors concerning inadequate disclosure regarding Jacobus’ 3,4-Dap as a cost-free and effective drug already in the marketplace. If you have information that could assist in this investigation, or if you are an Catalyst Pharmaceutical shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (firstname.lastname@example.org) by email or by phone at 619-230-0063, Ext. 118. Johnson & Weaver, LLP is a nationally recognized shareholders’ rights law firm. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Contact: Johnson & Weaver, LLP Jim Baker, 619-230-0063 Ext. 118 email@example.com